Efficacy of peroxisome proliferator activated receptor agonist in the treatment of virus-associated haemophagocytic syndrome in a rabbit model

Antiviral Therapy

Volumn 15, Issue 1, 2010, Pages 71-81

  Hsieh, Wen Chuan ^a   Lan, Bau Shin ^b   Chen, Yi Ling ^a   Chang, Yao ^a,b   Chuang, Huai Chia ^b   Su, Ih Jen ^a,b,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; EXPERIMENTAL RABBIT; HEMOPHAGOCYTIC SYNDROME; HERPES VIRUS; HERPES VIRUS INFECTION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LABORATORY TEST; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; VIRUS LOAD; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; CALLITHRIX; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; HYPOGLYCEMIC AGENTS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PPAR GAMMA; RABBITS; SIMPLEXVIRUS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIRUS REPLICATION;

EID: 77949412801     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1490     Document Type: Article

References (41)

1. Chuang HC, Lay JD, Hsieh WC, Su IJ. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci 2007; 98:1281-1287.
2. Ishii E, Ohga S, Imashuku S, et al. Review of hemophagocytic lymphohistiocytosis (HLH) in children with focus on Japanese experiences. Crit Rev Oncol Hematol 2005; 53:209-223.
3. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360:1831-1837.
4. To KF, Chan PK, Chan KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001; 63:242-246.
5. Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 2004; 3:69-75.
6. Su IJ. Perspectives on the pathogenesis and therapy of hemophagocytic syndrome. J Formos Med Assoc 2008; 107:277-280.
7. Lay JD, Chuang SE, Rowe M, Su IJ. Epstein-barr virus latent membrane protein-1 mediates upregulation of tumor necrosis factor-alpha in EBV-infected T cells: implications for the pathogenesis of hemophagocytic syndrome. J Biomed Sci 2003; 10:146-155.
8. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virusinfected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997; 100:1969-1979.
9. Chuang HC, Lay JD, Hsieh WC, et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood 2005; 106:3090- 3096.
10. Henter JI. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med Pediatr Oncol 2002; 38:305-309.
11. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70:341-367
12. Belfort R, Harrison SA, Brown K, et al. A placebocontrolled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355:2297-2307.
13. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
14. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
15. Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferatoractivated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000; 275:4541-4544.
16. Appel S, Mirakaj V, Bringmann A, Weck MM, Grunebach F, Brossart P. PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood 2005; 106:3888-3894.
17. Skolnik PR, Rabbi MF, Mathys JM, Greenberg AS. Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects. J Acquir Immune Defic Syndr 2002; 31:1-10.
18. Arnold R, Konig W. Peroxisome-proliferator-activated receptor-gamma agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells. Virology 2006; 346:427-439.
19. Hayashi K, Ohara N, Teramoto N, et al. An animal model for human EBV-associated hemophagocytic syndrome: herpesvirus papio frequently induces fatal lymphoproliferative disorders with hemophagocytic syndrome in rabbits. Am J Pathol 2001; 158:1533-1542.
20. Hayashi K, Teramoto N, Akagi T. Animal in vivo models of EBV-associated lymphoproliferative diseases: special references to rabbit models. Histol Histopathol 2002; 17:1293-1310.
21. Lee YS, Tanaka A, Lau RY, Nonoyama M, Rabin H. Comparative studies of herpesvirus papio (baboon herpesvirus) DNA and Epstein-Barr virus DNA. J Gen Virol 1980; 51:245-253.
22. Hsieh WC, Chang Y, Hsu MC, et al. Emergence of antired blood cell antibodies triggers red cell phagocytosis by activated macrophages in a rabbit model of Epstein-Barr virus-associated hemophagocytic syndrome. Am J Pathol 2007; 170:1629-1639.
23. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38:1008-1017.
24. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39:188-196.
25. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10:355-361.
26. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43:S99-S112.
27. Na HK, Surh YJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 2003; 66:1381-1391.
28. Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptorgamma, reduces acute inflammation. Eur J Pharmacol 2004; 483:79-93.
29. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A 2000; 97:10990-10995.
30. Lu J, Imamura K, Nomura S, et al. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res 2005; 65:4769-4774.
31. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p- substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 2006; 66:412-418.
32. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/ COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003; 17:2115-2117.
33. Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy 2004; 3:361-375.
34. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007; 22:1387-1398.
35. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007; 7:358-368.
36. Merx MW, Liehn EA, Graf J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005; 112:117-124.
37. Merx MW, Liehn EA, Janssens U, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004; 109:2560-2565.
38. Mishra S, Mishra JP, Kumar A. Activation of JNKdependent pathway is required for HIV viral protein R-induced apoptosis in human monocytic cells: involvement of antiapoptotic BCL2 and c-IAP1 genes. J Biol Chem 2007; 282:4288-4300.
39. Trujillo-Murillo K, Rincon-Sanchez AR, Martinez-Rodriguez H, et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 2008; 47:1462-1472.
40. Chang WW, Su IJ, Chang WT, Huang W, Lei HY. Suppression of p38 mitogen-activated protein kinase inhibits hepatitis B virus replication in human hepatoma cell: the antiviral role of nitric oxide. J Viral Hepat 2008; 15:490-497.
41. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-1207.